Physician profile
Robert D Mino
NPI 1265489983
$1,610.11
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,449 · 2020: $161.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $428.44 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $359.40 | 2019 | |
| Janssen Biotech, INC. | $292.69 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $198.03 | 2019 | |
| Ferring Pharmaceuticals INC. | $162.18 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $46.66 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.36 | 2019-2020 | |
| Neotract INC. | $39.49 | 2019 | |
| Amgen INC. | $23.87 | 2020 | |
| 180 Medical, INC. | $14.99 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.